Remarks from The Economist’s Health Care Forum: War on Cancer event on the opportunities and challenges ahead for the healthcare system.
The Health Care Forum: War on Cancer, held on September 29, 2015 in Boston, MA is a full-day conference designed for leaders in healthcare to discuss the opportunities and challenges ahead for the healthcare system. The event, hosted by The Economist, provides attendees with a forum for networking and discovering the latest industry developments, while bringing together cross-sector stakeholders into dialogue on cancer.
This year, the event sought to explore the role of collaboration and integration in driving innovation and progress in cancer care. The event also focused on innovative approaches and solutions across policy and financing, prevention, early detection, treatment and the long-term management of this deadly disease. Other featured topics included:
The quality of speakers at this event was fantastic, including speakers such as Bahija Jallal (Executive vice-president, Astrazeneca and head, MedImmune) who talked about new approaches to diagnostics and therapies, and Otis Brawley (Chief medical and scientific officer, executive vice-president of research, American Cancer Society) who talked about genetics, the environment and behaving better. Check out the full roster of speakers and agenda.
For me, the main takeaways of the day included:
It seems more and more likely that the biggest breakthroughs in cancer diagnostics and therapies will come within our lifetimes. We may never be completely cancer-free, but we’ll be a lot closer to that state if we continue to share information about technologies, costs and choices.
This was a wonderful event, providing leaders and stakeholders in the healthcare field a unique opportunity to meet and discuss the oncology space. If you’d like to know more, join us on Twitter using the hashtag #WarOnCancer.
For additional information on this topic, read about the outcomes of the 2015 Accenture-US National Cancer Institute panel: Searching for Value in Cancer Therapies.